Laura B. Goddard

Array ( [id] => 18117565 [patent_doc_number] => 11548946 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-10 [patent_title] => Carrier-PD-L1 binding agent compositions for treating cancers [patent_app_type] => utility [patent_app_number] => 16/330030 [patent_app_country] => US [patent_app_date] => 2017-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 28 [patent_no_of_words] => 17861 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16330030 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13699947 [patent_doc_number] => 20170360928 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-21 [patent_title] => GENE DETECTION ASSAY FOR IMPROVING THE LIKELIHOOD OF AN EFFECTIVE RESPONSE TO AN ErbB ANTAGONIST CANCER THERAPY [patent_app_type] => utility [patent_app_number] => 15/692808 [patent_app_country] => US [patent_app_date] => 2017-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10970 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15692808 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18187559 [patent_doc_number] => 11578128 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-14 [patent_title] => Anti-CTLA4 and anti-PD-1 bifunctional antibody, pharmaceutical composition thereof and use thereof [patent_app_type] => utility [patent_app_number] => 16/327076 [patent_app_country] => US [patent_app_date] => 2017-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 60 [patent_no_of_words] => 16009 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16327076 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19410605 [patent_doc_number] => 12076398 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-03 [patent_title] => Anti-PD1 monoclonal antibody, pharmaceutical composition thereof and use thereof [patent_app_type] => utility [patent_app_number] => 16/327083 [patent_app_country] => US [patent_app_date] => 2017-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 12 [patent_no_of_words] => 8030 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16327083 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12240214 [patent_doc_number] => 20180073078 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-15 [patent_title] => 'RNF41 AS A BIOMARKER PREDICTING RESPONSE TO LENALIDOMIDE IN NON-DEL(5Q) MDS' [patent_app_type] => utility [patent_app_number] => 15/682062 [patent_app_country] => US [patent_app_date] => 2017-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 6156 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15682062 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14531849 [patent_doc_number] => 20190201545 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-04 [patent_title] => CYTOTOXIC PARTICLES [patent_app_type] => utility [patent_app_number] => 16/326882 [patent_app_country] => US [patent_app_date] => 2017-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9628 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16326882 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17268515 [patent_doc_number] => 11193935 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-07 [patent_title] => Compositions, methods and kits for diagnosis of lung cancer [patent_app_type] => utility [patent_app_number] => 15/680656 [patent_app_country] => US [patent_app_date] => 2017-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 12171 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 188 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15680656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12765052 [patent_doc_number] => 20180146852 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-31 [patent_title] => MOLECULAR IMAGING METHODS FOR DIAGNOSIS AND EVALUATION OF OCULAR AND SYSTEMIC DISEASES [patent_app_type] => utility [patent_app_number] => 15/678534 [patent_app_country] => US [patent_app_date] => 2017-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18523 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15678534 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13314221 [patent_doc_number] => 20180208647 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-26 [patent_title] => VEGF-SPECIFIC ANTAGONISTS FOR ADJUVANT AND NEOADJUVANT THERAPY AND THE TREATMENT OF EARLY STAGE TUMORS [patent_app_type] => utility [patent_app_number] => 15/677804 [patent_app_country] => US [patent_app_date] => 2017-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43605 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15677804 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16443715 [patent_doc_number] => 10835619 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-11-17 [patent_title] => Targeted therapy to repolarize tumor-associated macrophages (TAMs) [patent_app_type] => utility [patent_app_number] => 15/677559 [patent_app_country] => US [patent_app_date] => 2017-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 5 [patent_no_of_words] => 8440 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 167 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15677559 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14581397 [patent_doc_number] => 20190218307 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => TIRC7 BASED DIAGNOSTIC AND THERAPY OF CANCER [patent_app_type] => utility [patent_app_number] => 16/324385 [patent_app_country] => US [patent_app_date] => 2017-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4453 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16324385 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15726841 [patent_doc_number] => 10611842 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-07 [patent_title] => Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPa antibody therapy [patent_app_type] => utility [patent_app_number] => 15/660510 [patent_app_country] => US [patent_app_date] => 2017-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 5 [patent_no_of_words] => 18301 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15660510 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16925315 [patent_doc_number] => 11046777 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-29 [patent_title] => Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/319590 [patent_app_country] => US [patent_app_date] => 2017-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 13 [patent_no_of_words] => 16354 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16319590 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15852999 [patent_doc_number] => 10641773 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-05 [patent_title] => Biomarker for diagnosis of extrahepatic bile duct carcinoma, intrahepatic bile duct carcinoma, or gallbladder carcinoma [patent_app_type] => utility [patent_app_number] => 15/656896 [patent_app_country] => US [patent_app_date] => 2017-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 14 [patent_no_of_words] => 7583 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15656896 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14475189 [patent_doc_number] => 20190189241 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-20 [patent_title] => Selecting Neoepitopes as Disease-Specific Targets for Therapy with Enhanced Efficacy [patent_app_type] => utility [patent_app_number] => 16/318895 [patent_app_country] => US [patent_app_date] => 2017-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31560 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -55 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16318895 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12023679 [patent_doc_number] => 20170313778 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-02 [patent_title] => 'MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/650429 [patent_app_country] => US [patent_app_date] => 2017-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 59618 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15650429 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14652811 [patent_doc_number] => 20190233534 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-01 [patent_title] => MULTIPLE BI-SPECIFIC BINDING DOMAIN CONSTRUCTS WITH DIFFERENT EPITOPE BINDING TO TREAT CANCER [patent_app_type] => utility [patent_app_number] => 16/317782 [patent_app_country] => US [patent_app_date] => 2017-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25501 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -110 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16317782 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12565980 [patent_doc_number] => 10017567 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-10 [patent_title] => Treatment of cancer with anti-LAP monoclonal antibodies [patent_app_type] => utility [patent_app_number] => 15/649235 [patent_app_country] => US [patent_app_date] => 2017-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 67 [patent_figures_cnt] => 96 [patent_no_of_words] => 48133 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15649235 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18461670 [patent_doc_number] => 11685954 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-27 [patent_title] => Biomarkers predictive of endocrine resistance in breast cancer [patent_app_type] => utility [patent_app_number] => 16/315861 [patent_app_country] => US [patent_app_date] => 2017-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 30 [patent_no_of_words] => 108118 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16315861 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12979825 [patent_doc_number] => 20170342146 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-30 [patent_title] => NANOBODIES AGAINST TUMOR NECROSIS FACTOR-ALPHA [patent_app_type] => utility [patent_app_number] => 15/644890 [patent_app_country] => US [patent_app_date] => 2017-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 98700 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15644890 [rel_patent_id] =>[rel_patent_doc_number] =>)